Pharma Research and Early Development (pRED)
Grenzacherstrasse 124
CH-4070 Basel
Switzerland
roche.com
Project leader
 |
|
| Mr. Martin Graf |
IMI StemBANCC Coordinator
Head of Stem Cell Platform
Discovery Technologies |
|
|
|
Project staff
 |
|
| Dr. Nicole Clemann |
WP10 co-leader
Non Clinical Safety |
|
|
|
 |
|
| Dr. Mark Burcin |
WP3 co-leader
Lab Leader, Stem Cell Platform
Discovery Technologies |
|
|
|
 |
|
| Mr. Klaus Christensen |
WP03
Lab Leader, Stem Cell Platform
Discovery Technologies |
|
|
|
 |
|
| Dr. Ravi Jagasia |
WP08 - CNS
Lab Leader, Neuroscience Discovery |
|
|
|
 |
|
| Dr. Hansruedi Loetscher |
WP08 - CNS
Head Molecular Neuroscience
Neuroscience Discovery |
|
|
|
 |
|
Dr. Anna-Lisa Gündner
|
WP08 - CNS
Post Doc, Neuroscience Discovery |
|
|
|
 |
|
Dr. Roberto Iacone
|
WP09 - Diabetes
Group Leader, Cardiovascular & Metabolic Diseases |
|
|
|
 |
|
| Dr. Osele Ciampi |
|
WP09 WP10
Post Doc, Cardiovascular & Metabolic Diseases |
|
|
|
Institute presentation
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.